Preclinical and clinical evidence suggest that low-dose cannabinoids could ameliorate Alzheimer's disease (AD) signs and symptoms. We designed this trial to evaluate the safety and efficacy of low-dose THC-CBD balanced cannabinoid extract in the treatment of patients with AD-associated dementia.
Objective
The objective of this phase 2 trial was to evaluate the safety and efficacy of a balanced THC-CBD cannabinoid extract for symptomatic patients with AD.
Methods
A Phase 2, randomized, double-blind, placebo-controlled, clinical trial including patients between 60 and 80 years-old diagnosed with AD-associated dementia. For 26 weeks, participants orally received either placebo or THC-CBD extract (0.350 mg/THC and 0.245 mg/CBD), daily.
Results
At week 26, Mini-Mental State Exam total score was significantly higher in cannabis- when compared to placebo-treated patients, which was assessed using the mixed model analysis. No significant difference was detected between placebo and cannabis groups in terms of secondary outcomes and adverse events incidence.
Conclusions
To this date, this is the longest clinical trial evaluating cannabinoids effects on AD patients. We initially demonstrate that low-dose THC-CBD potentially can be an effective and safe therapeutic option for AD-related dementia. Nonetheless, larger and longer trials are necessary to confirm this finding and establish cannabinoid administration as therapy for AD dementia.
Trial Registration
The Brazilian Registry of Clinical Trials (ReBEC) registration #U1111-1258-2058 - REBEC (ensaiosclinicos.gov.br).
ClineENBiccaMAViolaKL, et al.The amyloid-β oligomer hypothesis: beginning of the third decade. J Alzheimers Dis2018; 64: S567–S610.
3.
MicaleVMazzolaCDragoF. Endocannabinoids and neurodegenerative diseases. Pharmacol Res2007; 56: 382–392.
4.
Van Den ElsenGAHAhmedAIAVerkesRJ, et al.Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. Neurology2015; 84: 2338–2346.
5.
Martín-MorenoAMBreraBSpuchC, et al.Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation2012; 9: 8.
6.
BisognoTDi MarzoV. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets2012; 9: 564–573.
7.
KarlTChengDGarnerB, et al.The therapeutic potential of the endocannabinoid system for Alzheimer’s disease. Expert Opin Ther Targets2012; 16: 407–420.
8.
Bilkei-GorzoA. The endocannabinoid system in normal and pathological brain ageing. Philos Trans R Soc Lond B Biol Sci2012; 367: 3326–3341.
9.
BerrenderoFGarcía-GilLHernándezML, et al.Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development. Development1998; 125: 3179–3188.
10.
RomeroJBerrenderoFGarcia-GilL, et al.Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35S]guanylyl-5’-O-(thio)-triphosphate binding in the basal ganglia of aged rats. Neuroscience1998; 84: 1075–1083.
11.
ColesMWattGKreilausF, et al.Medium-dose chronic cannabidiol treatment reverses object recognition memory deficits of APP Swe/PS1ΔE9 transgenic female mice. Front Pharmacol2020; 11: 587604.
12.
Ruver-MartinsACBiccaMAde AraujoFS, et al.Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer’s disease symptoms: a case report. J Med Case Rep2022; 16: 277.
13.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 263–269.
WestBTWelchKBGaleckiAT. Linear Mixed Models: A Practical Guide Using Statistical Software. 3rd edition. New York: Chapman and Hall/CRC, 2022.
16.
Sabanes BoveDLiLDedicJ, et al.mmrm: Mixed Models for Repeated Measures (R package version 0.3.10), https://CRAN.R-project.org/package=mmrm.= (2024, accessed 9 March 2024).
17.
HowardRCostafredaSGKarcherK, et al.Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients. Br J Psychiatry2016; 209: 378–384.
18.
WeimerDLSagerMA. Early identification and treatment of Alzheimer's disease: social and fiscal outcomes. Alzheimers Dement2009; 5: 215–226.
19.
BullockRDengizA. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract2005; 59: 817–822.
20.
WhitingPFWolffRFDeshpandeS, et al.Cannabinoids for medical use: a systematic review and meta-analysis. JAMA2015; 313: 2456–2473.
21.
RogersSLFarlowMRDoodyRS, et al.A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology1998; 50: 136–145.
22.
PeskindERPotkinSGPomaraN, et al.Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry2006; 14: 704–715.
23.
WaltherSMahlbergREichmannU, et al.Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology2006; 185: 524–528.
24.
HerrmannNRuthirakuhanMGallagherD, et al.Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease. Am J Geriatr Psychiatry2019; 27: 1161–1173.
25.
CohenLMAshEOutenJD, et al.Study rationale and baseline data for pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's dementia (THC-AD). Int Psychogeriatr2024; 36: 1245–1250.
26.
KnappMKingDRomeoR, et al.Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer’s disease (the DOMINO-AD trial). Int J Geriatr Psychiatry2017; 32: 1205–1216.
27.
SöderbergLJohannessonMNygrenP, et al.Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer's disease. Neurotherapeutics2023; 20: 195–206.
28.
Van DyckCHSwansonCJAisenP, et al.Lecanemab in early Alzheimer’s disease. N Engl J Med2023; 388: 9–21.
29.
SimsJRZimmerJAEvansCD, et al.Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA2023; 330: 512–527.
30.
MullardA. FDA Approves third anti-amyloid antibody for Alzheimer disease. Nat Rev Drug Discov2024; 23: 571.
31.
Di MarzoVBifulcoMDe PetrocellisL. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov2004; 3: 771–784.
32.
SolasMFrancisPTFrancoR, et al.CB2 Receptor and amyloid pathology in frontal cortex of Alzheimer’s disease patients. Neurobiol Aging2013; 34: 805–808.
33.
EspositoGLuvoneTSavaniC, et al.Opposing control of cannabinoid receptor stimulation on amyloid-β-induced reactive gliosis: in vitro and in vivo evidence. J Pharmacol Exp Ther2007; 322: 1144–1152.
34.
EspositoGDe FilippisDSteardoL, et al.CB1 Receptor selective activation inhibits β-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. Neurosci Lett2006; 404: 342–346.
35.
ScuderiCSteardoLEspositoG. Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARγ involvement. Phyther Res2014; 28: 1007–1013.
36.
Bilkei-GorzoAAlbayramODraffehnA, et al.A chronic low dose of Δ9-tetrahydrocannabinol (THC) restores cognitive function in old mice. Nat Med2017; 23: 782–787.
37.
KarlTGarnerBChengD. The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer’s disease. Behav Pharmacol2017; 28: 142–160.
38.
PetrocellisLLigrestiAMorielloAS, et al.Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol2011; 163: 1479–1494.
39.
RussoEBBurnettAHallB, et al.Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res2005; 30: 1037–1043.
40.
ChengDSpiroASJennerAM, et al.Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice. J Alzheimers Dis2014; 42: 1383–1396.
41.
EspositoGScuderiCValenzaM, et al.Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS One2011; 6: e28668.
42.
Komorowska-MüllerJAGellnerAKRavichandranKA, et al.Chronic low-dose Δ9-tetrahydrocannabinol (THC) treatment stabilizes dendritic spines in 18-month-old mice. Sci Rep2023; 13: 1390.
43.
ColesMSteiner-LimGZKarlT. Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer’s disease. Front Neurosci2022; 16: 962922.
44.
VázquezCTolónRMGrandeMT, et al.Endocannabinoid regulation of amyloid-induced neuroinflammation. Neurobiol Aging2015; 36: 3008–3019.
45.
RatherAMKhanAWangL, et al.TRP Channels: role in neurodegenerative diseases and therapeutic targets. Heliyon2023; 9: e16910.
46.
LengFEdisonP. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?Nat Rev Neurol2021; 17: 157–172.
47.
HonigLSVellasBWoodwardM, et al.Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med2018; 378: 321–330.
48.
SallowaySChalkiasSBarkhofF, et al.Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol2022; 79: 13–21.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
